Home › Osteosarcoma › Washington › Seattle
Osteosarcoma clinical trials in Seattle, WA
5 studies for Osteosarcoma are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- Seattle Children's Hospital, Seattle
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
RecruitingPhase 1
- Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RecruitingPhase 3
- Seattle Children's Hospital, Seattle
SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
- Seattle Children's Hospital, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- Seattle Children's Hospital, Seattle
Osteosarcoma trials in other cities
- St. Louis, MO10 studies
- Memphis, TN10 studies
- Atlanta, GA10 studies
- Boston, MA9 studies
- Houston, TX9 studies
- Birmingham, AL7 studies
- Cincinnati, OH7 studies
- Mountain View, CA7 studies
- Los Angeles, CA7 studies
- Chicago, IL7 studies
- Dallas, TX6 studies
- Tampa, FL6 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.